23 Academy-ro
Yeonsu-gu
Incheon
South Korea
82 3 2850 5000
https://www.celltrion.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein:
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Hyong-Gi Kim | CEO & Internal Director | S.O. | S.O. | 1965 |
Mr. Woo-Sung Kee | CEO & Internal Director | S.O. | S.O. | 1961 |
Jin-seok Seo | Co-CEO & Inside Co-Chairman of the Board | S.O. | S.O. | S.O. |
Mr. Stephen Yeum | Founder | S.O. | S.O. | S.O. |
Mr. Min-Cheol Shin | Director of Finance | S.O. | S.O. | 1971 |
Mr. Ji-Hoon Choi | Director of Legal Affairs | S.O. | S.O. | 1971 |
Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea. The company markets bio pharmaceuticals; generic pharmaceuticals; covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 for the treatment of asthma and urticaria that is in phase 3 clinical trial; CT-P17 for the treatment of autoimmune diseases which is in phase 3 clinical trial; CT-P16 for the treatment of non-small cell lung cancer and colon cancer that is in phase 3 clinical trial; CT-P41 for the treatment of osteoporosis and bone loss, which is in phase 3 clinical trial; CT-P43 for the treatment of psoriasis, crohn's disease, and ulcerative colitis that is in phase 3 clinical trial; CT-P42 for the treatment of diabetic macular edema, which is in phase 3 clinical trial; CT-P47 for the treatment of rheumatoid arthritis, which is in phase 3 clinical trial; CT-P27 for the treatment of pandemic/seasonal influenza that is in phase 2 clinical trial; and CT-G20 for the treatment of Cardiomyopathy that is in phase 1 clinical trial. The company was founded in 2002 and is headquartered in Incheon, South Korea.
L’ISS Governance QualityScore de Celltrion, Inc. en date du 1 mai 2024 est 3. Les scores principaux sont Audit : 1; Société : 4; Droits des actionnaires : 4; Compensation : 1.